Cyclic Dipeptide CHP Regenerates Beta-Cell Mass
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes and β-cell failure primarily focus on insulin resistance or elevation, with limited options for preventing β-cell failure and restoring function, and existing antidiabetic drugs often come with undesirable side effects or are unsuitable for pregnancy.
Innovation Solution
Administration of cyclo (His-Pro) (CHP) alone or in combination with zinc and other antidiabetic drugs to regenerate and protect insulin-secreting β-cell mass, thereby addressing β-cell failure and associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antidiabetic drugs are used to treat type 2 diabetes, then insulin resistance or insulin levels are improved, but undesirable side effects occur
Solution Approach 1:
The patent changes the therapeutic parameter from targeting insulin resistance or insulin elevation to targeting β-cell function preservation and regeneration. CHP and zinc alter the biochemical parameters of β-cells, improving their function and mass without the side effects associated with conventional antidiabetic drugs.
Solution Approach 2:
The patent introduces CHP and zinc as intermediary substances that mediate between the harmful effects of chronic hyperglycemia and β-cell damage. These intermediaries protect β-cells from oxidative stress and promote their regeneration, providing a safer therapeutic approach.
2Reliability
If current antidiabetic drugs are used to treat type 2 diabetes, then blood glucose control is improved, but suitability for pregnancy is reduced
Solution Approach 1:
The patent changes the therapeutic approach to use CHP and zinc, which have different safety profiles compared to conventional antidiabetic drugs. These substances can be used during pregnancy to control blood glucose without the teratogenic effects or contraindications associated with current medications.
3Reliability
If dietary and lifestyle changes are implemented to prevent or treat prediabetes, then β-cell function is improved, but patient compliance deteriorates
Solution Approach 1:
The patent introduces CHP and zinc as pharmacological intermediaries that can achieve β-cell protection and regeneration without requiring patients to maintain complex dietary and lifestyle changes. This intermediary approach simplifies the treatment regimen while maintaining therapeutic effectiveness.
4Stress or pressure
If chronic glucose intolerance and elevated blood glucose levels persist, then β-cell workload is reduced, but β-cell mass loss and functional deterioration accelerate
Solution Approach 1:
The patent applies preliminary anti-action by using CHP and zinc to protect β-cells from the damaging effects of chronic hyperglycemia before significant mass loss and functional deterioration occur. These substances preemptively reduce oxidative stress and inflammation, preventing the accelerated β-cell damage that would otherwise result from persistent glucose intolerance.
Data Source
AI summary
A method and composition for treating and/or preventing β-cell dysfunction and/or protecting impaired β-cells are disclosed. The method includes administering an effective amount of cyclo (his-pro) (CHP), alone or with zinc, to a subject. The composition contains an effective amount of cyclo (his-pro) (CHP) as an active ingredient. The composition may further contain zinc and/or other antidiabetic agent, or can be administered in combination with zinc and/or other antidiabetic agent.